FDA grants full approval for Inluriyo plus Verzenio in ESR1-mutated breast cancer
FDA granted full approval to Lilly’s Inluriyo (imlunestrant) plus Verzenio (abemaciclib) for adults with ER+, HER2—, ESR1— mutated advanced or metastatic breast cancer after at least one line of endocrine therapy, based on EMBER-3.
Story updates
05:55:21 PM UTC
SquawkNews
The FDA granted full approval to Lilly’s Inluriyo (imlunestrant) plus Verzenio (abemaciclib) for adults with ER+, HER2—, ESR1—mutated advanced or metastatic breast cancer after at least one line of endocrine therapy, based on EMBER—3 showing median PFS 11.1 vs 5.5 months.Material DetailsContext by…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.